These Were the Top 5 Venture Capital Deals in Houston in 2021

Tvardi Therapeutics Inc. has fresh funds to support its drug’s advancement in clinical trials. Photo via Getty Images

Cancer-Fighting Company Based in Houston Emerges from Stealth and Snags $74M in its Latest Round

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

“We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors,” says Imran Alibhai, CEO at Tvardi. “With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team.” Click here to read the full article

SOURCE:
InnovationMap, by Natalie Harms

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.